New Data from the Largest Contemporary Analysis of Valvular Heart Disease Prevalence in the United States

“This is the first prevalence study out of one of the largest echo databases in the world, underscoring the potential for groundbreaking research from this tremendous resource. Our work expands by an order of magnitude the sample size and generalizability of previous work in a large contemporary cohort.”

J. Matthew Brennan, M.D., M.P.H., Associate Professor of Medicine, Interventional Cardiology, Duke University School of Medicine, and lead author of the study.

New data1,2 demonstrates valvular heart disease (VHD) is more common in women in the U.S. Other key findings suggest tricuspid and mitral regurgitation have the highest prevalence rates, with severe mitral regurgitation being more frequently diagnosed in centers offering transcatheter mitral repair technologies.

This study is the largest contemporary analysis of the prevalence of VHD, with previous landmark analyses including the the Framingham Heart Study3 and Nkomo et al4. The study, sponsored by egnite, evaluates the prevalence of aortic stenosis (AS), aortic regurgitation (AR), mitral stenosis (MS), mitral regurgitation (MR), and tricuspid regurgitation (TR) in the U.S. and has been published as an abstract in the Journal of the American College of Cardiology (JACC)1 and presented at the American College of Cardiology 71st Annual Scientific Session (ACC.22)2.

The analysis, which was performed on data from over 714,000 patients (represented by over 929,000 echocardiograms), found the prevalence of VHD by type (%) to be as follows: TR (7.1%), MR (6.5%), AS (4.1%), AR (2.3%), and MS (0.5%).

Click the image to view highlights of the results!

Follow egnite on social:

References

  1. Brennan JM, Petrescu M, McCarthy P, et al. Contemporary prevalence of valvular heart disease & diagnostic variability across centers. J Am Coll Cardiol. 2022;79(9_Suppl):1723.
  2. Brennan JM, Petrescu M, McCarthy P, et al. Contemporary prevalence of valvular heart disease & diagnostic variability across centers. Poster presented at: American College of Cardiology 71st Annual Scientific Session & Expo; April 2–4, 2022; Washington, DC.
  3. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6):897-902.
  4. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-11.

Related Articles

AI Alliance

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.

Real-World Evidence

Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly

Press

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital